SCHEDULE: Junyi Dai Updates Indaptus Therapeutics Ownership Stake

Junyi Dai reports a change in his beneficial ownership percentage of Indaptus Therapeutics due to an increase in the company's total outstanding shares.

Summary

• Junyi Dai, CEO and Chairman of Indaptus Therapeutics, Inc., filed an amendment to his Schedule 13D.
• The reporting person maintains beneficial ownership of 11,250,000 shares of common stock.
• The ownership percentage decreased to 8.44% from previous levels due to the issuance of additional shares by the company in a private placement on June 17, 2026.
• The total number of outstanding shares for the issuer is reported as 133,242,324 as of June 24, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure; the change in ownership is purely technical and driven by corporate financing rather than a change in the insider's confidence.

Positives

• The reporting person remains a significant shareholder with 11,250,000 shares.
• The change in ownership percentage is purely dilutive due to corporate capital activity rather than a divestment by the CEO.

Negatives

• The reporting person's ownership percentage has been diluted due to the company's recent private placement.

Risks

• Dilution of existing shareholders resulting from the issuance of new common stock.
• Reliance on the company's ability to successfully execute its business strategy following recent capital raises.

Future Outlook

The filing does not provide specific forward-looking guidance regarding company operations, focusing instead on the disclosure of ownership changes.

Industry Context

StockSavvy.ai notes that this filing reflects standard regulatory compliance for biotech executives following corporate financing rounds that result in share dilution.

Comparison to Industry Standards

• The filing adheres to standard SEC disclosure requirements for beneficial owners holding more than 5% of a company's equity.
• Dilution events are common in the clinical-stage biotechnology sector as companies raise capital to fund ongoing research and development.

Stakeholder Impact

• Existing shareholders experience dilution due to the increase in total outstanding shares.

Next Steps

• Continued monitoring of Indaptus Therapeutics' capital structure and future SEC filings.

Key Dates

Keywords

Indaptus Therapeutics, Schedule 13D, Junyi Dai, Beneficial Ownership, Stock Dilution, Biotech